ARLINGTON, Va.--(BUSINESS WIRE)--Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), today announced that it has entered into a royalty agreement with Concordia Pharmaceuticals for the use of Salirasib, Concordia’s novel compound for the treatment of cancer, in combination with another targeted drug. Under the terms of the agreement, Champions will use its Biomerk Tumorgraft™ Preclinical Platform to evaluate a combination therapy indication for Salirasib, a RAS antagonist. This agreement modifies an earlier preclinical services agreement between the companies and now provides royalty rights for Champions Biotechnology for a specific combination therapy indication for Salirasib in the event that required milestones are achieved.
